139 related articles for article (PubMed ID: 30518812)
1. Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance.
Cristofoletti C; Bresin A; Picozza M; Picchio MC; Monzo F; Helmer Citterich M; Passarelli F; Frezzolini A; Scala E; Monopoli A; Cantonetti M; Benucci R; D'Atri S; Caprini E; Russo G; Narducci MG
Leukemia; 2019 May; 33(5):1231-1242. PubMed ID: 30518812
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of PTEN status in Sezary syndrome.
Cristofoletti C; Picchio MC; Lazzeri C; Tocco V; Pagani E; Bresin A; Mancini B; Passarelli F; Facchiano A; Scala E; Lombardo GA; Cantonetti M; Caprini E; Russo G; Narducci MG
Blood; 2013 Nov; 122(20):3511-20. PubMed ID: 24062018
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma.
Bresin A; Cristofoletti C; Caprini E; Cantonetti M; Monopoli A; Russo G; Narducci MG
J Invest Dermatol; 2020 May; 140(5):1045-1053.e6. PubMed ID: 31682844
[TBL] [Abstract][Full Text] [Related]
4. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
5. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
Narducci MG; Tosi A; Frezzolini A; Scala E; Passarelli F; Bonmassar L; Monopoli A; Accetturi MP; Cantonetti M; Antonini Cappellini GC; De Galitiis F; Rosato A; Picozza M; Russo G; D'Atri S
Front Immunol; 2020; 11():579894. PubMed ID: 33072126
[TBL] [Abstract][Full Text] [Related]
6. Skin homing of Sézary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV.
Narducci MG; Scala E; Bresin A; Caprini E; Picchio MC; Remotti D; Ragone G; Nasorri F; Frontani M; Arcelli D; Volinia S; Lombardo GA; Baliva G; Napolitano M; Russo G
Blood; 2006 Feb; 107(3):1108-15. PubMed ID: 16204308
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
8. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
[TBL] [Abstract][Full Text] [Related]
9. Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases.
Klemke CD; Booken N; Weiss C; Nicolay JP; Goerdt S; Felcht M; Géraud C; Kempf W; Assaf C; Ortonne N; Battistella M; Bagot M; Knobler R; Quaglino P; Arheiliger B; Santucci M; Jansen P; Vermeer MH; Willemze R
Br J Dermatol; 2015 Jul; 173(1):93-105. PubMed ID: 25864856
[TBL] [Abstract][Full Text] [Related]
10. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.
Silva JM; Bulman C; McMahon M
Mol Cancer Res; 2014 Mar; 12(3):447-63. PubMed ID: 24425783
[TBL] [Abstract][Full Text] [Related]
11. Extracellular Glutamate-Induced mTORC1 Activation via the IR/IRS/PI3K/Akt Pathway Enhances the Expansion of Porcine Intestinal Stem Cells.
Zhu M; Qin YC; Gao CQ; Yan HC; Li XG; Wang XQ
J Agric Food Chem; 2019 Aug; 67(34):9510-9521. PubMed ID: 31382738
[TBL] [Abstract][Full Text] [Related]
12. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.
van der Fits L; van Kester MS; Qin Y; Out-Luiting JJ; Smit F; Zoutman WH; Willemze R; Tensen CP; Vermeer MH
J Invest Dermatol; 2011 Mar; 131(3):762-8. PubMed ID: 21085192
[TBL] [Abstract][Full Text] [Related]
14. Impact of mTORC1 inhibition on keratinocyte proliferation during skin tumor promotion in wild-type and BK5.AktWT mice.
Rho O; Kiguchi K; Jiang G; DiGiovanni J
Mol Carcinog; 2014 Nov; 53(11):871-82. PubMed ID: 24114993
[TBL] [Abstract][Full Text] [Related]
15. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
[TBL] [Abstract][Full Text] [Related]
16. The miR-139-5p regulates proliferation of supratentorial paediatric low-grade gliomas by targeting the PI3K/AKT/mTORC1 signalling.
Catanzaro G; Besharat ZM; Miele E; Chiacchiarini M; Po A; Carai A; Marras CE; Antonelli M; Badiali M; Raso A; Mascelli S; Schrimpf D; Stichel D; Tartaglia M; Capper D; von Deimling A; Giangaspero F; Mastronuzzi A; Locatelli F; Ferretti E
Neuropathol Appl Neurobiol; 2018 Dec; 44(7):687-706. PubMed ID: 29478280
[TBL] [Abstract][Full Text] [Related]
17. EPHA4 is overexpressed but not functionally active in Sézary syndrome.
Hameetman L; van der Fits L; Zoutman WH; Out-Luiting JJ; Siegal G; de Esch IJ; Vermeer MH; Tensen CP
Oncotarget; 2015 Oct; 6(31):31868-76. PubMed ID: 26376612
[TBL] [Abstract][Full Text] [Related]
18. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
19. A novel mouse model for Sézary syndrome using xenotransplantation of Sézary cells into immunodeficient RAG2(-/-) γc(-/-) mice.
van der Fits L; Rebel HG; Out-Luiting JJ; Pouw SM; Smit F; Vermeer KG; van Zijl L; Tensen CP; Weijer K; Vermeer MH
Exp Dermatol; 2012 Sep; 21(9):706-9. PubMed ID: 22897578
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM
Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
